related documents
- Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson's disease (PD) from OFF to fully ON: preliminary results from a phase iii study Conferences
- Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: results from the Phase 3 study dose-titration phase Conferences
- Motor dysfunctions in rats following repeated exposure to stress on the neurotoxicity of lambda-cyhalothrin Conferences
- Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: preliminary results from a Phase III Study Conferences
- Study design of an efficacy and safety phase 3, randomized, double-blind, placebo-controlled trial of APL-130277 in the treatment of OFF episodes (CTH-300) Conferences